Comparison of Leishmania typing results obtained from 16 European clinical laboratories in 2014. by Van der Auwera, Gert et al.
Van der Auwera, G; Bart, A; Chicharro, C; Cortes, S; Davidsson,
L; Di Muccio, T; Dujardin, JC; Felger, I; Paglia, MG; Grimm, F;
Harms, G; Jaffe, CL; Manser, M; Ravel, C; Robert-Gangneux, F;
Roelfsema, J; Tz, S; Verweij, JJ; Chiodini, PL (2016) Comparison of
Leishmania typing results obtained from 16 European clinical labo-
ratories in 2014. Euro surveillance , 21 (49). ISSN 1025-496X DOI:
10.2807/1560-7917.ES.2016.21.49.30418
Downloaded from: http://researchonline.lshtm.ac.uk/3234022/
DOI: 10.2807/1560-7917.ES.2016.21.49.30418
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
1www.eurosurveillance.org
Research article 
Comparison of Leishmania typing results obtained from 
16 European clinical laboratories in 2014
G Van der Auwera ¹ , A Bart ² , C Chicharro ³ , S Cortes ⁴ , L Davidsson ⁵ , T Di Muccio ⁶ , J Dujardin 1 7 , I Felger 8 9 , MG Paglia 10 , F 
Grimm 11 , G Harms 12 , CL Jaffe 13 , M Manser 14 , C Ravel 15 , F Robert-Gangneux 16 , J Roelfsema 17 , S Töz 18 , JJ Verweij 19 , PL Chiodini 
20 21 
1. Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
2. Academic Medical Center, Amsterdam, The Netherlands
3. Instituto de Salud Carlos III, Madrid, Spain
4. Global Health and Tropical Medicine, GHTM, Instituto de Higiene e Medicina Tropical, UNL, Lisbon, Portugal
5. The Public Health Agency of Sweden, Stockholm, Sweden
6. Istituto Superiore di Sanità, Rome, Italy
7. Biomedical Sciences, Antwerp University, Antwerp, Belgium
8. Swiss Tropical and Public Health Institute, Basel, Switzerland
9. University of Basel, Basel, Switzerland
10. National Institute for Infectious Diseases (INMI) Lazzaro Spallanzani, Rome, Italy
11.  Institute of Parasitology, University of Zürich, Zürich, Switzerland
12. Institute of Tropical Medicine and International Health, Charité-Universitätsmedizin Berlin, Berlin, Germany
13. Hebrew University, Hadassah Medical Centre, Jerusalem, Israel
14. United Kingdom National External Quality Assessment Service, London, United Kingdom
15. University of Montpellier, Montpellier, France
16. Centre Hospitalier Universitaire de Rennes, Rennes, France
17.  National Institute for Public Health and the Environment, RIVM, Bilthoven, The Netherlands
18. Ege University, Faculty of Medicine, Department of Parasitology, Izmir, Turkey
19. St. Elisabeth Hospital, Tilburg, The Netherlands
20. Hospital for Tropical Diseases, London, United Kingdom
21. London School of Hygiene and Tropical Medicine, London, United Kingdom
Correspondence: Gert Van der Auwera (gvdauwera@itg.be)
Citation style for this article: 
Van der Auwera G, Bart A, Chicharro C, Cortes S, Davidsson L, Di Muccio T, Dujardin J, Felger I, Paglia MG, Grimm F, Harms G, Jaffe CL, Manser M, Ravel C, Robert-
Gangneux F, Roelfsema J, Töz S, Verweij JJ, Chiodini PL. Comparison of Leishmania typing results obtained from 16 European clinical laboratories in 2014. Euro 
Surveill. 2016;21(49):pii=30418. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2016.21.49.30418 
Article submitted on 08 January 2016 / accepted on 13 July 2016 / published on 08 December 2016
Leishmaniasis is endemic in southern Europe, and 
in other European countries cases are diagnosed 
in travellers who have visited affected areas both 
within the continent and beyond. Prompt and accu-
rate diagnosis poses a challenge in clinical practice 
in Europe. Different methods exist for identification 
of the infecting Leishmania species. Sixteen clinical 
laboratories in 10 European countries, plus Israel and 
Turkey, conducted a study to assess their genotyping 
performance. DNA from 21 promastigote cultures of 
13 species was analysed blindly by the routinely used 
typing method. Five different molecular targets were 
used, which were analysed with PCR-based methods. 
Different levels of identification were achieved, and 
either the Leishmania subgenus, species complex, or 
actual species were reported. The overall error rate of 
strains placed in the wrong complex or species was 
8.5%. Various reasons for incorrect typing were iden-
tified. The study shows there is considerable room 
for improvement and standardisation of Leishmania 
typing. The use of well validated standard operating 
procedures is recommended, covering testing, inter-
pretation, and reporting guidelines. Application of 
the internal transcribed spacer 1 of the rDNA array 
should be restricted to Old World samples, while the 
heat-shock protein 70 gene and the mini-exon can be 
applied globally.
Introduction
Leishmaniasis is a vector-borne disease which is 
endemic in 98 countries worldwide [1]. It is caused by 
protozoan parasites of the genus Leishmania, which 
are transmitted by female sand flies of the genera 
Lutzomyia and Phlebotomus. Many infected individuals 
never develop symptoms, but those who do can exhibit 
various disease manifestations [2]. Visceral leishma-
niasis (VL) or kala-azar is the severe form, whereby 
parasites infect internal organs and the bone marrow, 
a lethal condition if left untreated. Other disease types 
are restricted to the skin (cutaneous leishmaniasis, 
CL) or the mucosae of the nose and mouth (mucosal 
leishmaniasis, ML). Finally, a particular cutaneous dis-
ease sometimes develops in cured VL patients: post 
kala-azar dermal leishmaniasis (PKDL). Typically, VL 
is caused by two species: Leishmania donovani and 
Leishmania infantum. The latter can also cause CL, 
as can all other pathogenic species. Some particular 
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species (e.g. L. braziliensis and L. aethiopica) can lead 
to overt ML.
As many as 20 different Leishmania species are able 
to infect humans, and globally there are over 1 million 
new disease cases per annum [1,3]. Leishmaniasis is 
endemic in southern Europe, and in other European 
countries cases are diagnosed in travellers who 
have visited affected areas both within the continent 
and beyond. Although treatment in practice is often 
guided only by clinical presentation and patient his-
tory, in some cases determination of the aetiological 
subgenus, species complex or species is recommended 
for providing optimal treatment [2,4,5]. For exam-
ple, a patient returning from South America with CL 
might be infected with Leishmania braziliensis, which 
necessitates systemic drug therapy and counselling 
about the risk of developing mucosal leishmaniasis 
in the future. The same patient could also be infected 
with Leishmania mexicana, which is managed by less 
intensive treatment and which is not associated with 
mucosal disease [6]. Determining the infecting spe-
cies and its probable source permits selection of the 
Figure 1
Typing results obtained in study comparing Leishmania typing results in 16 European clinical laboratories, 2014
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Figure 2
Typing results for each of the 21 strains included in study comparing Leishmania typing results in 16 European clinical 
laboratories, 2014
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MLSA: multilocus sequence analysis; WHO: World Health Organization.
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b Strain MHOM/CO/88/UA316 is L. guyanensis based on MLEE, but L. panamensis based on MLSA (Table 1).
For each strain, the number of correct typings at species, species complex, and subgenus level are reported. In addition, the incorrect species 
designations are indicated, some of which identified the wrong species in the correct complex (purple bars), others placing an isolate in the 
wrong complex (red bars). The strain identification by WHO code (Table 1) is given with the abscissa. Species, complexes, and subgenera 
are represented on top, with an indication of the New or Old World strain origin.
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correct drug, route of administration (intralesional, 
oral systemic, or parenteral) and duration [7].
Unfortunately, for CL it is impossible to predict the 
species responsible for an ulcerating lesion clinically, 
and the morphology of amastigotes does not differ 
between species. When the geographical origin of 
infection is known, for instance when a patient in an 
endemic region is treated at a local hospital, the spe-
cies can be guessed often from the known local epide-
miology, as species distribution follows a geographical 
pattern [8]. However, especially in infectious disease 
clinics that treat patients who have stayed in various 
endemic countries, the geographic origin of infections 
may be unknown. For instance, people residing in 
Europe who have travelled outside Europe may come 
from, or have also visited, Leishmania-endemic areas 
within Europe, especially the Mediterranean basin. 
Even when the location of infection is known, sev-
eral species can co-circulate in a given endemic area, 
in which case the species can only be determined by 
laboratory tests. Culture and subsequent isoenzyme 
analysis is time consuming and available in very few 
specialised centres, so it is impractical as a front-line 
diagnostic test in clinical laboratories. Hence, well-per-
formed reliable molecular methods are necessary for 
species identification.
Several Leishmania typing methods have been pub-
lished (reviewed in [9]), and as a result each laboratory 
uses its own preferred assay. The most popular assays 
nowadays are those that can be applied directly to clin-
ical samples, thereby circumventing the need for para-
site isolation and culture. However, few tests have been 
standardised, and no commercial kits are currently 
available. As a result, clinical and epidemiological 
studies make use of various techniques, and in patient 
management other methods are often deployed. In this 
study we compare the typing performance in 16 clini-
cal laboratories across Europe, which use a variety of 
methods for species discrimination.
Table 1
Strains used, study comparing Leishmania typing results in 16 European clinical laboratories, 2014
Strain (WHO code) Culture name CNRLa Speciesb Reference typing methodc
MHOM/ET/83/130–83 LEM1118 Leishmania aethiopica MLEE, MLSA
MHOM/GF/2002/LAV003 LEM4351 L. amazonensis MLEE, MLSA
MHOM/VE/76/JAP78 LEM0391 L. amazonensis MLEE, MLSA
MHOM/BR/75/M2903b LEM0396 L. braziliensis MLEE, MLSA
MHOM/PE/83/STI139 LEM0781 L. braziliensis MLEE, MLSA
MHOM/BO/2001/CUM555 NA L. braziliensis outlierd AFLP [12], WGS, MLSA
MHOM/IN/--/LRC-L51 LEM1070 L. donovani MLEE, MLSA
MHOM/KE/55/LRC-L53 LEM0707 L. donovani MLEE, MLSA
MHOM/GF/86/LEM1034 LEM1034 L. guyanensis MLEE, MLSA
MHOM/FR/78/LEM75 LEM0075 L. infantum MLEE, MLSA
MCUN/BR/85/M9342 LEM2229 L. lainsoni MLEE, MLSA
MHOM/IQ/86/CRE1 LEM0858 L. major MLEE, MLSA
MHOM/BZ/82/BEL21 LEM0695 L. mexicana MLEE, MLSA
MHOM/EC/87/EC103-CL8 LEM1554 L. mexicana MLEE, MLSA
MDAS/BR/79/M5533 LEM2204 L. naiffi MLEE, MLSA
MHOM/CO/86/UA126 LEM1047 L. panamensis MLEE, MLSA
MHOM/CO/88/UA264 LEM1492 L. panamensis MLEE, MLSA
MHOM/CO/88/UA316 LEM1505 L. panamensis / L. guyanensise MLEE, MLSA
MHOM/PE/90/HB86 NA L. peruviana AFLP [12], WGS, MLSA
MHOM/PE/90/LCA08 NA L. peruviana AFLP [12], WGS, MLSA
MHOM/IL/80/SINGER LEM0617 L. tropica MLEE, MLSA
AFLP: amplified fragment length polymorphism; CNRL: Centre National de Référence des Leishmanioses (Montpellier, France); NA: not 
applicable; MLEE: multilocus enzyme electrophoresis; MLSA: multilocus sequence analysis; WGS: whole genome sequencing; WHO: World 
Health Organization.
a Identification in the Montpellier cryobank (Centre National de Référence des Leishmanioses).
b For the taxonomic position of each species (subgenus and species complex), please refer to Figure 2.
c Reference method used to determine the species of each isolate. MLEE [10]; MLSA based on seven genes [11]; AFLP analysis [12]; WGS 
(unpublished results).
d Group of distinct Leishmania braziliensis strains [9,12], also called L. braziliensis type 2 [15] or atypical L. braziliensis [18].
e This strain was typed as L. panamensis by MLSA, and as L. guyanensis by MLEE.
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Methods
Participants and reference methods
Twenty one Leishmania isolates were typed by 16 labo-
ratories in 12 countries in 2014. Table 1 lists the par-
asite strains that were used in this study, along with 
the reference method for species identification. Strains 
identified with a Laboratoire d’Ecologie Médicale 
(LEM) code were provided by the Centre National de 
Référence des Leishmanioses in Montpellier, France, 
which assigns LEM codes to each cryopreserved cul-
ture, while the remaining three strains were provided by 
the Institute of Tropical Medicine in Antwerp, Belgium.
Four highly informative reference methods were used: 
multilocus enzyme electrophoresis (MLEE [10]), multi-
locus sequence analysis (MLSA [11], GenBank sequence 
accession numbers in Table 2), genome-wide amplified 
fragment length polymorphism (AFLP) analysis [12], 
and whole genome sequencing (unpublished results).
DNA was extracted from parasite cultures using either 
the DNeasy Blood and Tissue Kit or QIAamp DNA Mini 
Kit (Qiagen, www.qiagen.com), and the concentration 
was measured spectrophotometrically. The 21 DNAs 
were randomised at the United Kingdom (UK) National 
External Quality Assessment Service for Parasitology 
(UKNEQAS, London, UK), and every study participant 
received a blind panel containing 50 µl of a 10 ng/µl 
DNA solution. The participating laboratories are listed 
in Table 3.
After performing the respective routine typing technol-
ogy, each laboratory reported its results to UKNEQAS, 
who forwarded these along with the randomised code 
in one batch to the Institute of Tropical Medicine in 
Antwerp for analysis. Some participants used the 
term ‘L. braziliensis complex’ when referring to the L. 
(Viannia) subgenus, and where needed the reported 
results were adjusted. The results after these adjust-
ments are presented in this analysis.
Genome targets for typing
The 16 laboratories used a total of five genome targets 
for typing (Table 4): the internal transcribed spacer 1 
of the rDNA array (ITS1), the mini-exon, kinetoplast 
minicircle DNA (kDNA), the heat-shock protein 70 gene 
(hsp70), and a repetitive DNA sequence. One laboratory 
reported two sets of result from two different targets, 
which are treated in the analysis as if they were from 
separate laboratories, which is why the results section 
describes 17 instead of 16 outcomes. The targets were 
Table 2
GenBank sequence accession numbers from MLSA and hsp70, for sequences used in study comparing Leishmania typing 
results in 16 European clinical laboratories, 2014
WHO CODE LEM
MLSA locus
hsp70 
3,0980 4,0580 10,0560 12,0010 14,0130 31,0280 31,2610
MCUN/BR/85/M9342 2229 KT959002 KT959017 KT959032 KT959047 KT959062 KT959077 KT959092 LN907839
MDAS/BR/79/M5533 2204 KT959001 KT959016 KT959031 KT959046 KT959061 KT959076 KT959091 FR872767
MHOM/BO/2001/CUM555 NA KT959006 KT959021 KT959036 KT959051 KT959066 KT959081 KT959096 FR872760
MHOM/BR/75/M2903b 396 KT958993 KT959008 KT959023 KT959038 KT959053 KT959068 KT959083 LN907832
MHOM/BZ/82/BEL21 695 KT958994 KT959009 KT959024 KT959039 KT959054 KT959069 KT959084 LN907841
MHOM/CO/86/UA126 1047 KT958997 KT959012 KT959027 KT959042 KT959057 KT959072 KT959087 LN907843
MHOM/CO/88/UA264 1492 KT958998 KT959013 KT959028 KT959043 KT959058 KT959073 KT959088 LN907844
MHOM/CO/88/UA316 1505 KT958999 KT959014 KT959029 KT959044 KT959059 KT959074 KT959089 LN907837
MHOM/EC/87/EC103-CL8 1554 KT959000 KT959015 KT959030 KT959045 KT959060 KT959075 KT959090 LN907842
MHOM/ET/83/130–83 1118 KC159315 KC159537 KC159093 KC159759 KC158871 KC159981 KC158649 LN907830
MHOM/FR/78/LEM75 75 KC159255 KC159477 KC159033 KC159699 KC158811 KC159921 KC158589 LN907838
MHOM/GF/2002/LAV003 4351 KT959003 KT959018 KT959033 KT959048 KT959063 KT959078 KT959093 LN907831
MHOM/GF/86/LEM1034 1034 KT958996 KT959011 KT959026 KT959041 KT959056 KT959071 KT959086 LN907836
MHOM/IL/80/SINGER 617 KC159287 KC159509 KC159065 KC159731 KC158843 KC159953 KC158621 LN907846
MHOM/IN/--/LRC-L51 1070 KC159313 KC159535 KC159091 KC159757 KC158869 KC159979 KC158647 LN907834
MHOM/IQ/86/CRE1 858 KC159299 KC159521 KC159077 KC159743 KC158855 KC159965 KC158633 LN907840
MHOM/KE/55/LRC-L53 707 KC159294 KC159516 KC159072 KC159738 KC158850 KC159960 KC158628 LN907835
MHOM/PE/1990/HB86 NA KT959004 KT959019 KT959034 KT959049 KT959064 KT959079 KT959094 LN907845
MHOM/PE/1990/LCA08 NA KT959005 KT959020 KT959035 KT959050 KT959065 KT959080 KT959095 EU599089
MHOM/PE/83/STI139 781 KT958995 KT959010 KT959025 KT959040 KT959055 KT959070 KT959085 LN907833
MHOM/VE/76/JAP78 391 KT958992 KT959007 KT959022 KT959037 KT959052 KT959067 KT959082 EU599092
LEM: Laboratoire d’Ecologie Médicale; MLSA: multilocus sequence analysis; hsp70: heat-shock protein 70 gene; NA: not applicable; WHO: 
World Health Organization.
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analysed with PCR, generally followed by sequencing 
or restriction fragment length polymorphism (RFLP) 
analysis, as shown in Table 4 and Figure 1. Four labo-
ratories used in-house sequencing, while five others 
used the service of an external sequencing facility. 
PCRs based on kDNA did not require post-PCR manipu-
lations other than gel analysis.
Figure 1 indicates for each laboratory individually which 
method or methods were used, but not all samples 
were necessarily analysed with each method. Of the 
16 laboratories, 11 used the ITS1 target, either applying 
RFLP (n=7) or sequencing (n=4). All of them based their 
analysis on the fragment described in [13], except for 
laboratory L which used a larger region also including 
ITS2 [14]. Five laboratories based typing on hsp70: four 
(A-D) used sequencing of the F fragment described in 
[15-17], while one (E) used the N fragment. Two labo-
ratories (F and G) analysed this gene with RFLP [17,18]. 
Three laboratories used sequence analysis of the mini-
exon gene: laboratory O [19,20], laboratory P [21], and 
laboratory Q [22]. Two laboratories based typing partly 
on kDNA: laboratory K [23], and laboratory L [24,25]. 
Finally, laboratory J complemented ITS1-RFLP with RFLP 
analysis of a repetitive DNA sequence [26].
Grading of results
Each individual result was graded as follows. The best 
ranking was given to reported species agreeing with the 
reference methods, whereby L. garnhami was consid-
ered a synonym of L. amazonensis [27]. Results report-
ing MHOM/BO/2001/CUM555 as L. braziliensis were 
considered correct. Although this strain belongs to a 
group of clearly distinguishable outliers (Table 1), it has 
so far not been described as a separate species. Next 
were identifications that reported the species complex 
rather than the actual species (see Figure 2), and were 
in agreement with the reference methods. The lowest 
ranking of correct results was given to those identify-
ing the subgenus, i.e. L. (Viannia) or L. (Leishmania), 
without specification of species or species complex. 
Identification errors were graded at two levels. First, 
some laboratories reported a species within the cor-
rect complex, but identified the wrong species within 
that complex. Second, some isolates were placed in 
an erroneous species complex altogether. A peculiar 
case was presented by strain MHOM/CO/88/UA316, 
which was L. guyanensis based on MLEE, but L. pan-
amensis based on MLSA (Table 1). For this strain, all 
results reporting either L. guyanensis or L. panamensis 
were considered to have identified the correct species 
complex.
In a next level of the analysis, the cause of erroneous 
typings was sought by means of in-depth assessment 
of the methods. The reasons for different identifica-
tion outcomes of laboratories using the same methods 
were also identified. Sequences from laboratories that 
based their typing on the same genes were compared 
by alignment in the software package MEGA5 [28].
Results
Results from all analyses are summarised in Figure 1, 
details are available from [29]. One laboratory reported 
Table 3
Participants in study comparing Leishmania typing results in 16 European clinical laboratories, 2014
Institute City Country
Institute of Tropical Medicine Antwerpa Antwerp Belgium
Centre National de Référence des Leishmaniosesa,b Montpellier France
Centre Hospitalier Universitaire de Rennes Rennes France
Charité-Universitätsmedizin Berlin Berlin Germany
Hebrew University-Hadassah Medical Centre Jerusalem Israel
Istituto Superiore di Sanità Rome Italy
National Institute for Infectious Diseases L. Spallanzani Rome Italy
Instituto de Higiene e Medicina Tropical Lisbon Portugal
Instituto de Salud Carlos III Majadahonda Spain
The Public Health Agency of Sweden Stockholm Sweden
Swiss Tropical and Public Health Institutea Basel Switzerland
Institute of Parasitology Zürich Switzerland
Academic Medical Center, University of Amsterdam Amsterdam The Netherlands
National Institute for Public Health and the Environment Bilthoven The Netherlands
St. Elisabeth Hospital Tilburg The Netherlands
Ege University Medical School Izmir Turkey
Hospital for Tropical Diseases London United Kingdom
Institutes are listed in alphabetical order based on country and city.
a These laboratories provided parasite cultures and DNA.
b This laboratory applied one of the reference methods (MLSA) and did not participate in the comparative study of typing outcomes.
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two sets of results because identification based on 
hsp70 sequences was sometimes in conflict with those 
of ITS1 sequencing. These results are listed separately 
from laboratories E and M respectively, which brings 
the number of reported result sets from the 16 labora-
tories to 17. Most laboratories succeeded in typing all 
21 samples, but in some cases results were reported 
for 20/21 isolates only (laboratories D, K, L, M). The 
total number of erroneous identifications amounted 
to 30, with 23 of these being classified in an incorrect 
species complex. On a total of 353 results, these rep-
resent 8.5% and 6.5% respectively. The correct species 
was identified in 211 typing results (60%), while 58 
(16%) identified the correct species complex, and 54 
(15%) the correct subgenus. Eight laboratories made no 
incorrect assignments, while the laboratory with most 
errors (laboratory J) misidentified 10 out of 21 sam-
ples, seven of which were placed in the wrong species 
complex. Laboratories relying only on kDNA and ITS1 
more frequently reported results to the subgenus level, 
while laboratories using the mini-exon or hsp70 often 
succeeded in obtaining identification either to the spe-
cies or complex level.
Figure 2 depicts the typing results for each strain, irre-
spective of the methods used. The only two species 
that were correctly identified with all methods were L. 
tropica and L. major. Strains from the L. (Leishmania) 
subgenus were identified to either the species or com-
plex level by all laboratories. This was in contrast to 
the 11 strains from the L. (Viannia) subgenus, each 
of which was typed by four to six laboratories only to 
the subgenus level. The error rate for both subgenera 
was comparable: 8.4% (14/167) for L. (Leishmania) and 
8.6% (16/186) for L. (Viannia). The error rate in Old 
World strains was lower than for strains of the New 
World: 5.9% (6/102) and 9.6% (24/251) respectively.
When comparing the hsp70 sequences provided by 
four laboratories (A-D), there were marked differences 
in sequence quality. Three laboratories (A, B, C) suc-
ceeded in sequencing the entire or nearly entire frag-
ment F [17], with few or no sequence ambiguities. The 
sequence sets of two laboratories (A and C) contained 
one insertion and one deletion relative to the other 
data, indicating sequence mistakes as the gene shows 
no size variation [15,16]. In contrast, the quality of the 
fragment F sequences from one laboratory (D) was 
considerably lower. Sequences were largely incomplete 
at their 5’ end and to a lesser extent at their 3’ termi-
nus, and numerous insertions, deletions, and unre-
solved nucleotides (nt) were present. One laboratory 
(E) sequenced only the N fragment [17], but base call-
ing quality was poor in the 40 terminal 3’ nt. The con-
sensus hsp70 sequences were deposited in GenBank 
(Table 2).
Three laboratories (M, N, O) determined the ITS1 
sequence of all isolates, while one laboratory (P) 
sequenced only MHOM/GF/2002/LAV003. The 
sequences of two laboratories (N and P) covered the 
entire amplified PCR product, while some of two others 
(O and M) were incomplete at the termini. Apart from 
some insertions in the sequences of one laboratory 
(N) and occasional unresolved nt in those of another 
(O), the sequences were identical, except for isolate 
MHOM/CO/88/UA316. Here, up to 9 nt differences were 
present in a 120 nt stretch.
Three laboratories (O, P, Q) determined the mini-exon 
sequences. For some strains the sequences of these 
laboratories were nearly identical, but for others large 
size differences of the determined fragment were 
seen, and deletions and nt identity discrepancies were 
observed. Also, many nt were not fully resolved.
Discussion
As a general observation, eight laboratories who par-
ticipated in this comparison typing performance made 
no errors, and often laboratories using the same typ-
ing marker reported different results (Figure 1). Two of 
the ‘error-free’ laboratories obtained the highest typ-
ing accuracy, with 20 out of 21 strains typed to the 
species level, and strain MHOM/CO/88/UA316 at the 
complex level. Using our reference methods MLSA and 
MLEE (Table 1), the latter species could not be classi-
fied unequivocally, and hence results placing it in the 
L. guyanensis complex were regarded as correct. These 
two laboratories (A and B) based their typing on hsp70 
gene sequencing, which was identified as one of the 
typing methods with the highest resolution in other 
comparative studies [9,15]. One other laboratory (C) 
also made use of this method, but typed several strains 
only to the complex level. Even though the hsp70 gene 
often permits distinction between closely related spe-
cies, separating them is not always straight-forward. 
For instance, some MLEE-defined L. guyanensis have 
the same sequence as L. panamensis [16]. Because 
identifying the exact species within a given complex 
Table 4
Typing methods used in study comparing Leishmania 
typing results in 16 European clinical laboratories, 2014
Genomic locus / gene Analysis method Number of laboratoriesa
ITS1 RFLP [13,14] 7
Sequencing [15] 4
hsp70 Sequencing [15,16] 5
RFLP [17] 2
Mini-exon Sequencing [19-21] 3
kDNA minicircles RFLP [24,25] 1
Specific PCR [23] 1
Repetitive DNA RFLP [26] 1
ITS: internal transcribed spacer; hsp70: heat-shock protein 70 
gene; kDNA: kinetoplast minicircle DNA; RFLP: restriction 
fragment length polymorphism.
a The total number is higher than the 16 participating laboratories, 
because several laboratories used different methods in parallel.
8 www.eurosurveillance.org
can therefore be difficult, one laboratory (C) decided 
to identify the species complex rather than the exact 
species in case of doubt. Apparently the low sequence 
quality obtained by one of the participants (D) had 
no adverse effects on the results, probably because 
species-specific nt identities were not affected. The 
sequence quality was not influenced by the use of in-
house vs external sequencing services.
One laboratory (E) reported four mistakes based on 
hsp70 sequences. As opposed to laboratories A-D, the 
analysis was based on a smaller part of the gene, frag-
ment N [17], which is not suited for typing all species 
[15]. Nevertheless, several of these species were called 
based on a BLAST search in GenBank [https://blast.
ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch], 
from which the first listed species was regarded as the 
final result, regardless of identical similarity scores 
obtained from other species. In this process some spe-
cies were by chance determined correctly, while others 
were erroneously identified. This stresses the impor-
tance of correctly interpreting output lists generated by 
BLAST, because different species can have the same 
similarity score when the marker is too conservative for 
discriminating between them. To avoid such errors the 
species complex rather than the species itself should 
have been reported. On one occasion, the applied 
methodology even identified an erroneous complex, 
i.e. MHOM/ET/83/130–83 was typed as L. donovani 
instead of L. aethiopica, based on an erroneous anno-
tation in GenBank. Indeed, several GenBank entries of 
[30] were wrongfully submitted as L. donovani, while 
they derived in fact from other species [16]. This illus-
trates the importance of critically evaluating BLAST 
results, and underscores the importance of an agreed 
reference panel of sequences from trustworthy labo-
ratories and knowledge of the limitations of a typing 
marker.
The same laboratory E reported a second results set 
based on ITS1 sequence analysis, listed under labora-
tory M in Figure 1. Again, BLAST analysis was applied, 
and even though ITS1 is not suitable for discriminating 
L. braziliensis and L. guyanensis complex species [15], 
several species were reported. Except for one misclas-
sified L. braziliensis outlier strain (Figure 2), species 
were correctly assigned by laboratory M. However, in 
several cases also other species showed the same sim-
ilarity scores, and hence there was no ground for nam-
ing the exact species. In contrast, another laboratory 
(N), which also used ITS1 sequence analysis, reported 
L. (Viannia) strains at subgenus level with no further 
attempt to determine the complex or species. Thereby 
they respected the limitations of ITS1, although some 
L. (Viannia) complexes could have been identified 
based on their data.
The majority of study participants that used ITS1 did 
not sequence the target, but relied on RFLP analy-
sis. Laboratories basing their results on this method 
reported some typical errors: L. tropica was mixed up 
with L. aethiopica; the L. donovani complex was con-
fused with L. mexicana; unsuccessful attempts were 
made to separate L. infantum from L. donovani; and 
on one occasion L. amazonensis was identified as L. 
major. When digesting the PCR products with the popu-
lar enzyme HaeIII, sufficient gel resolution is needed 
in order not to mix up the aforementioned species, as 
their RFLP fragments are similar in size. In addition, 
contrary to what was originally published [13], L. infan-
tum cannot be distinguished from L. donovani [9] and 
therefore ITS1 can only type to the L. donovani com-
plex, without further specification.
Two laboratories (F and G) complemented ITS-RFLP with 
hsp70-RFLP, and both mistook L. naiffi for L. brazilien-
sis. This is a result of identical patterns generated from 
L. naiffi and many L. braziliensis strains with restriction 
endonucleases HaeIII and RsaI. The mistake could have 
been avoided by using the appropriate enzyme SduI 
[18].
Only one laboratory (J) made use of a repetitive DNA 
sequence originally described in [31]. In combina-
tion with ITS1, 10 out of the 21 typings were incorrect, 
whereby seven strains were assigned to the wrong 
complex. Of the 10 mistakes, nine were made in the L. 
(Viannia) subgenus, while the remaining error was due 
to the unsuccessful separation of L. infantum from L. 
donovani. ITS1-RFLP is not suitable for discriminating 
these species, and the repetitive sequence RFLP was 
designed for typing Old World strains, where only the 
L. (Leishmania) subgenus is encountered. Such mis-
takes once more underline the importance of knowing 
the limits of the typing marker chosen.
Kinetoplast DNA is primarily a useful marker to discrim-
inate the two Leishmania subgenera, but is less suited 
for typing to the actual species level (reviewed in [9]). 
In combination with the fact that also ITS1-RFLP does 
not discriminate many L. (Viannia) species, the two lab-
oratories (K and L) using these methods reported typ-
ing mostly to the subgenus or species complex level. 
One of them (K) had a particularly high error rate (6/20) 
using these markers, probably related to the previously 
mentioned gel resolution problems and separation of 
L. infantum from L. donovani with ITS1-RFLP. In addition 
the laboratory used ‘L. braziliensis complex / L. guyan-
ensis complex’ as a synonym for L. (Viannia), while two 
strains were L. naiffi and L. lainsoni.
With the mini-exon sequences, only two mistakes 
were reported. One laboratory (O) identified L. mexi-
cana strain MHOM/EC/87/EC103-CL8 as L. donovani, 
but after disclosing the results realised a mistake in 
reporting, as their analysis actually did show the cor-
rect species. In a comparative analysis of four markers 
[15], the mini-exon together with hsp70 were identified 
as the most discriminative markers worldwide, which is 
confirmed by the results presented here. Some species 
within the complexes can, however, not be resolved 
based on the mini-exon, as also reflected in the current 
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analysis, where often complexes rather than species 
were identified.
When looking at the typing results for each of the 21 
strains (Figure 2), it is apparent that strains of the L. 
(Viannia) subgenus were more often typed to the sub-
genus level, while those of the L. (Leishmania) sub-
genus were more often reported at the species level. 
Given that ITS1 was the most popular marker, this is 
a logical result in view of the poor discrimination of 
L. (Viannia) species by ITS1. Also the fact that for Old 
World strains 5.9% of typings were erroneous, in com-
parison to 9.6% New World strains, relates to the use 
of methods that are tailored to Old World strains. Only 
two strains were identified to the species level by all 
laboratories and all methods: MHOM/IL/80/SINGER 
(L. tropica) and MHOM/IQ/86/CRE1 (L. major). The 
results show that several laboratories are currently 
unable to discriminate L. (Viannia) species, which is 
partly explained by the participation in the study of six 
groups that are situated in a European country where 
Leishmania is actively transmitted. Hence, they mainly 
diagnose patients infected by endemic species, and 
use methods primarily tailored to species in the Old 
World. On the contrary, the remaining laboratories are 
dealing only with imported leishmaniasis cases, which 
can originate from anywhere in the world, and for 
which the origin of infection is sometimes unknown. 
This forces them to apply assays that are able to iden-
tify species from everywhere around the globe.
With regard to nomenclature, there is an evident 
need for standardisation. When the first results were 
reported, several laboratories used the term ‘L. bra-
ziliensis complex’ to refer to L. (Viannia). For many 
years these have been synonyms, but current literature 
restricts this term to L. braziliensis and L. peruviana 
[27]. Another confusion can arise from the fact that 
each complex bears the name of one of its constituent 
species. For instance, a typing outcome reported as 
‘L. guyanensis’ has to be clearly distinguished from ‘L. 
guyanensis complex’. Even though this particular prob-
lem did not seem to occur in our analysis, one could 
easily envision such occurrence. One laboratory (K) 
reported several results as ‘L. braziliensis complex / 
L. guyanensis complex’ for referring to L. (Viannia), but 
with this term L. naiffi and L. lainsoni were excluded.
Finally, the particular case of strain MHOM/CO/88/
UA316 draws attention to problems in species defini-
tions, as this strain was typed as L. guyanensis with 
MLEE, but as L. panamensis with MLSA (Table 1). 
Reported correct results for this strain were either L. 
guyanensis complex, L. guyanensis, or L. panamensis, 
but this was irrespective of the method or target used 
[29]. Such occasional dubious results are unavoidable 
when dealing with closely related species, in particular 
L. guyanensis-L. panamensis; L. braziliensis-L. peruvi-
ana; L. mexicana-L. amazonensis; and L. donovani-L. 
infantum [9]. Also newly documented parasite species 
such as L. martiniquensis [32] and L. waltoni [33], and 
variants as the L. braziliensis outlier [9,12,15,18] fur-
ther complicate the interpretation of typing results. It 
is therefore of utmost importance that species identi-
fication is performed with a well-documented standard 
operating procedure (SOP), clearly describing not only 
experimental procedures, but also in detail how results 
should be analysed, interpreted, and reported.
The current study was performed on cultured parasite 
isolates, so all participants received a high amount of 
pure parasite DNA. Yet, 8.5% errors were seen, and in 
four cases no result was obtained. When dealing with 
patient material, the amount of parasite DNA is much 
lower, and vastly exceeded by human DNA. As the cur-
rent study did not assess the sensitivity of the meth-
ods used, it is expected that typing success based on 
clinical samples will be considerably lower. In view of 
the fact that only recognised reference laboratories 
participated in this study, there is a clear need for opti-
misation. On the other hand, in many clinical settings 
the suspected origin of infection can help in interpreta-
tion of typing outcomes, thereby possibly lowering the 
error rate.
Conclusions
There is considerable room for improvement of cur-
rent Leishmania typing strategies, and inter-labora-
tory comparisons such as the one we conducted can 
contribute to enhance typing quality. Whichever the 
clinical need for determining the subgenus, complex, 
or species, and whichever the technology used in a 
particular setting, typing should be based on a well-
defined and validated SOP designed by an expert in 
Leishmania taxonomy. This SOP should cover not only 
testing, but also analysis and interpretation proce-
dures, and a clear description of how species should 
be named and reported, taking into account the limita-
tions of each marker and technique, and the problem 
of resolving closely related species or occasional inter-
species hybrids. Validation should be performed on a 
sufficient amount of reference isolates from various 
geographic origins to cover each species’ variability. 
When using sequencing, sequence errors should be 
avoided, and a well-validated sequence reference set 
is recommended over BLAST analysis using GenBank, 
which lacks quality control. In cases where treatment 
is species- or complex-dependent, clinicians should be 
made aware of the limitations of the technology used 
whenever results are reported, especially when closely 
related species are involved. The use of real-time PCR 
assays developed for specific complexes or species 
could speed up typing and facilitate interpretation of 
results, but currently no globally applicable methods 
are available. As previously recommended [15] and 
also apparent from this analysis, hsp70 and the mini-
exon currently offer the best Leishmania typing tools 
world-wide, and the use of ITS1 should be restricted 
to the Old World. Setting up similar evaluations out-
side Europe, in institutes in endemic as well as non-
endemic countries, would shed additional light on the 
quality of Leishmania typing across the globe.
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